IL2 and renal cell adenocarcinoma: A randomized study comparing high- and low-dose IL-2 in 156 patients with metastatic renal cancer by Yang et al. [14], supported the finding that low-dose IL-2 regimens can cause the regression of advanced renal cell cancer.